Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-09-04 8:45 pm Sale | 2024-08-30 | 13D | Tango Therapeutics, Inc. TNGX | Third Rock Ventures IV, L.P. | 17,001,475 15.900% | -2,362,500 (-12.20%) | Filing History |
| 2024-04-08 08:46 am Unchanged | 2024-04-08 | 13G | Tango Therapeutics, Inc. TNGX | Southpoint Master Fund, LP | 5,276,699 4.900% | 0 (Unchanged) | Filing History |
| 2024-02-14 4:08 pm Purchase | 2023-12-31 | 13G | Tango Therapeutics, Inc. TNGX | Southpoint Master Fund, LP | 5,276,699 5.200% | 776,699 (+17.26%) | Filing History |
| 2024-02-13 4:51 pm Unchanged | 2023-12-31 | 13G | Tango Therapeutics, Inc. TNGX | GILEAD SCIENCES INC. GILD | 4,854,443 4.800% | 0 (Unchanged) | Filing History |
| 2024-02-09 09:49 am Sale | 2024-02-08 | 13G | Tango Therapeutics, Inc. TNGX | FMR LLC | 9,787,350 9.596% | -3,760,722 (-27.76%) | Filing History |
| 2023-10-18 5:23 pm Purchase | 2023-10-16 | 13D | Tango Therapeutics, Inc. TNGX | BCTG Holdings, LLC | 15,214,053 15.000% | 1,075,000 (+7.60%) | Filing History |
| 2023-10-16 3:33 pm Purchase | 2023-10-13 | 13G | Tango Therapeutics, Inc. TNGX | EcoR1 Capital, LLC | 13,330,736 13.100% | 5,503,100 (+70.30%) | Filing History |
| 2023-09-21 5:16 pm Purchase | 2023-09-11 | 13G | Tango Therapeutics, Inc. TNGX | EcoR1 Capital, LLC | 7,827,636 7.700% | 7,827,636 (New Position) | Filing History |
| 2023-09-11 08:23 am Purchase | 2023-09-08 | 13G | Tango Therapeutics, Inc. TNGX | FMR LLC | 13,548,072 13.326% | 4,464,393 (+49.15%) | Filing History |
| 2023-08-21 4:16 pm Purchase | 2023-08-11 | 13G | Tango Therapeutics, Inc. TNGX | Nextech Crossover I GP S.a. r.l. | 5,533,980 5.400% | 5,533,980 (New Position) | Filing History |
| 2023-08-16 4:40 pm Purchase | 2023-08-11 | 13D | Tango Therapeutics, Inc. TNGX | BCTG Holdings, LLC | 14,139,053 13.900% | 7,150,603 (+102.32%) | Filing History |
| 2023-02-14 3:02 pm Sale | 2022-12-31 | 13G | Tango Therapeutics, Inc. TNGX | Cormorant Asset Management, LP | 4,116,949 4.670% | -782,235 (-15.97%) | Filing History |
| 2023-02-13 9:34 pm Sale | 2022-12-31 | 13G | Tango Therapeutics, Inc. TNGX | Casdin Capital LLC | 0 0.000% | -5,487,910 (Position Closed) | Filing History |
| 2023-02-09 12:39 pm Purchase | 2023-02-09 | 13G | Tango Therapeutics, Inc. TNGX | FMR LLC | 9,083,679 8.291% | 1,901,491 (+26.48%) | Filing History |
| 2022-07-11 4:01 pm Purchase | 2022-06-30 | 13G | Tango Therapeutics, Inc. TNGX | Southpoint Master Fund, LP | 4,500,000 5.100% | 1,500,000 (+50.00%) | Filing History |
| 2022-02-14 4:11 pm Purchase | 2021-12-31 | 13G | Tango Therapeutics, Inc. TNGX | RA Capital Management, L.P. | 2,250,000 2.600% | 2,250,000 (New Position) | Filing History |
| 2022-02-14 3:17 pm Purchase | 2021-12-31 | 13G | Tango Therapeutics, Inc. TNGX | Cormorant Asset Management, LP | 4,899,184 5.600% | 4,899,184 (New Position) | Filing History |
| 2022-02-10 4:31 pm Purchase | 2021-12-31 | 13G | Tango Therapeutics, Inc. TNGX | Southpoint Master Fund, LP | 3,000,000 3.400% | 3,000,000 (New Position) | Filing History |
| 2022-02-09 10:01 am Purchase | 2022-02-08 | 13G | Tango Therapeutics, Inc. TNGX | FMR LLC | 7,182,188 6.593% | 7,182,188 (New Position) | Filing History |
| 2022-01-04 5:03 pm Unchanged | 2021-08-10 | 13D | Tango Therapeutics, Inc. TNGX | BCTG Holdings, LLC | 6,988,450 8.000% | 0 (Unchanged) | Filing History |